ILMN

278.17

5.14% 13.60

Dopo l'orario di chiusura: 278.00 -0.17 -0.06%

Illumina Inc (ILMN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$264.57

Aprire:

$268.21

Volume 24 ore:

1.89M

Relative Volume:

0.64

Capitalizzazione di mercato:

$42.00B

Reddito:

$4.39B

Utile/perdita netta:

$853.00M

Rapporto P/E:

50.49

EPS:

5.5097

Flusso di cassa netto:

$556.00M

1 W Prestazione:

+1.88%

1M Prestazione:

+35.69%

6M Prestazione:

+124.93%

1 anno Prestazione:

+188.41%

Intervallo 1D:

$265.25

$278.59

Intervallo di 1 settimana:

$254.00

$309.35

Portata 52W:

$88.00

$309.35

Illumina Inc Stock (ILMN) Company Profile

Nome

Illumina Inc

Settore

Healthcare (1050)

Industria

Diagnostics & Research (44)

Telefono

(858) 202-4500

Indirizzo

5200 ILLUMINA WAY, SAN DIEGO, CA

Dipendente

8,600

Cinguettio

@illumina

Prossima data di guadagno

2026-10-29

Ultimi documenti SEC

ILMN's Discussions on Twitter

Compare ILMN vs TMO, DHR, NTRA, A, IQV

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ILMN Illumina Inc	278.17	42.00B	4.39B	853.00M	556.00M	5.5097
TMO Thermo Fisher Scientific Inc	658.02	243.30B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	219.81	154.52B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	400.71	57.76B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	170.54	48.08B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	259.88	42.78B	16.63B	1.39B	2.12B	8.0674

Illumina Inc Stock (ILMN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-09-09	Ripresa	UBS	Buy
2026-06-26	Ripresa	Bernstein	Mkt Perform
2026-06-10	Aggiornamento	JP Morgan	Neutral → Overweight
2026-05-15	Ripresa	RBC Capital Mkts	Outperform
2026-05-14	Aggiornamento	Daiwa Securities	Neutral → Outperform
2025-08-12	Downgrade	Daiwa Securities	Outperform → Neutral
2025-07-11	Downgrade	Scotiabank	Sector Outperform → Sector Perform
2025-03-04	Reiterato	Citigroup	Neutral
2025-02-28	Downgrade	HSBC Securities	Buy → Hold
2025-02-10	Downgrade	Barclays	Equal Weight → Underweight
2025-02-07	Downgrade	TD Cowen	Buy → Hold
2024-12-11	Downgrade	Citigroup	Buy → Neutral
2024-11-12	Ripresa	Morgan Stanley	Equal-Weight
2024-10-17	Aggiornamento	HSBC Securities	Hold → Buy
2024-08-28	Aggiornamento	Argus	Hold → Buy
2024-08-16	Aggiornamento	Daiwa Securities	Neutral → Buy
2024-08-14	Aggiornamento	Barclays	Underweight → Equal Weight
2024-08-14	Aggiornamento	TD Cowen	Hold → Buy
2024-07-10	Aggiornamento	Citigroup	Neutral → Buy
2024-06-03	Ripresa	Jefferies	Hold
2024-01-16	Downgrade	HSBC Securities	Buy → Hold
2024-01-04	Downgrade	TD Cowen	Outperform → Market Perform
2023-12-18	Aggiornamento	Scotiabank	Sector Perform → Sector Outperform
2023-12-15	Aggiornamento	Bernstein	Underperform → Mkt Perform
2023-12-14	Iniziato	Guggenheim	Buy
2023-12-14	Iniziato	Stephens	Overweight
2023-12-13	Iniziato	Wolfe Research	Outperform
2023-12-12	Downgrade	BofA Securities	Neutral → Underperform
2023-12-11	Aggiornamento	Citigroup	Sell → Neutral
2023-11-10	Downgrade	Canaccord Genuity	Buy → Hold
2023-09-28	Iniziato	Bernstein	Underperform
2023-07-05	Ripresa	JP Morgan	Neutral
2023-01-25	Downgrade	Argus	Buy → Hold
2023-01-05	Iniziato	Scotiabank	Sector Perform
2022-12-12	Downgrade	Citigroup	Neutral → Sell
2022-12-07	Iniziato	RBC Capital Mkts	Outperform
2022-10-04	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2022-09-28	Aggiornamento	Evercore ISI	In-line → Outperform
2022-08-25	Iniziato	Credit Suisse	Neutral
2022-07-13	Downgrade	Barclays	Equal Weight → Underweight
2022-01-18	Aggiornamento	Stifel	Hold → Buy
2022-01-11	Aggiornamento	Barclays	Underweight → Equal Weight
2022-01-07	Aggiornamento	BofA Securities	Underperform → Neutral
2022-01-06	Ripresa	Morgan Stanley	Equal-Weight
2022-01-06	Ripresa	Piper Sandler	Overweight
2021-10-15	Ripresa	Cowen	Outperform
2021-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
2021-06-01	Aggiornamento	Evercore ISI	Underperform → In-line
2021-03-31	Downgrade	Atlantic Equities	Overweight → Neutral
2021-03-31	Aggiornamento	Canaccord Genuity	Hold → Buy
2021-03-03	Iniziato	Barclays	Underweight
2020-12-22	Aggiornamento	Piper Sandler	Neutral → Overweight
2020-12-17	Aggiornamento	BTIG Research	Neutral → Buy
2020-10-13	Downgrade	Guggenheim	Buy → Neutral
2020-09-30	Iniziato	Atlantic Equities	Overweight
2020-09-29	Downgrade	Wolfe Research	Outperform → Peer Perform
2020-09-22	Downgrade	Stifel	Buy → Hold
2020-09-22	Downgrade	UBS	Buy → Neutral
2020-09-21	Aggiornamento	Guggenheim	Neutral → Buy
2020-09-21	Downgrade	JP Morgan	Overweight → Neutral
2020-09-09	Iniziato	Morgan Stanley	Equal-Weight
2020-08-07	Downgrade	Evercore ISI	In-line → Underperform
2020-08-07	Downgrade	Piper Sandler	Overweight → Neutral
2020-07-07	Downgrade	Guggenheim	Buy → Neutral
2020-04-24	Downgrade	Citigroup	Buy → Neutral
2020-04-21	Downgrade	Robert W. Baird	Outperform → Neutral
2020-01-08	Iniziato	Wells Fargo	Underweight
2020-01-07	Iniziato	Citigroup	Buy
2020-01-02	Downgrade	Evercore ISI	Outperform → In-line
2019-11-15	Iniziato	Stifel	Buy
2019-10-25	Iniziato	Guggenheim	Buy

Mostra tutto

Illumina Inc Borsa (ILMN) Ultime notizie

Oct 06, 2026

Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.

Oct 06, 2026

Illumina Inc Stock (ILMN) Moved Up by 7.85% on Oct 5: Drivers Behind the Movement - TradingKey

Oct 05, 2026

Illumina rises as recent analyst target hikes and index inclusion keep momentum intact - Quiver Quantitative

Oct 05, 2026

Illumina stock hits 52-week high at 280.44 USD By Investing.com - Investing.com South Africa

Oct 05, 2026

Illumina stock hits 52-week high at 280.44 USD - Investing.com

Oct 05, 2026

Illumina's Clinical Sequencing Revenue Seen as Durable Mid-Teens Grower, RBC Capital Markets Says - marketscreener.com

Oct 05, 2026

Illumina's Clinical Sequencing Revenue Seen as Durable Mid-Teens Grower, RBC Capital Markets Says - Yahoo Finance

Oct 05, 2026

RBC Capital raises Illumina stock price target on clinical sales - Investing.com

Oct 05, 2026

RBC Capital maintains Outperform rating on Illumina, $310 price target - TradingView

Oct 05, 2026

RBC raises target for Illumina stock to USD 310 - AD HOC NEWS

Oct 05, 2026

Illumina Inc : RBC Raises Target Price to $31 - Moomoo

Oct 05, 2026

Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.

Oct 05, 2026

Oct 02, 2026

Form 4 Illumina Inc For: 2 October By Investing.com - Investing.com South Africa

Oct 02, 2026

A director receives 107 shares instead of cash for quarterly retainer fees at Illumina (ILMN). - Stock Titan

Oct 02, 2026

A director receives stock for 100% of Q3 retainer fees at Illumina (ILMN) - Stock Titan

Oct 02, 2026

Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 02, 2026

Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 02, 2026